Aberrant Alternative Splicing Events in Parkinson's Disease

• Published in: Cell Transplantation Vol. 22; no. 4; pp. 653 - 661
• Main Authors: Fu, Ru-Huei, Liu, Shih-Ping, Huang, Shyh-Jer, Chen, Hung-Jen, Chen, Pin-Ru, Lin, Ya-Hsien, Ho, Yu-Chen, Chang, Wen-Lin, Tsai, Chang-Hai, Shyu, Woei-Cherng, Lin, Shinn-Zong
• Format: Book Review Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.04.2013; SAGE Publishing
• Subjects: Alternative Splicing - genetics; Animals; Humans; Parkinson Disease - diagnosis; Parkinson Disease - genetics; Parkinson Disease - therapy; Prognosis; Alternative splicing (AS); Trans-acting splicing factors; Cis-regulatory elements; Parkinson's disease (PD)
• ISSN: 0963-6897; 1555-3892
• DOI: 10.3727/096368912X655154

Alternative splicing (AS) using a sole gene to express multiple transcripts with diverse protein coding sequences and/or RNA regulatory elements raises genomic complexities. In the nervous system, several thousand AS events play important roles in ion transportation, receptor recognition, neurotransmission, memory, and learning. Not surprisingly, AS influences human physiology, development, and disease. Many research studies have focused on aberrant AS in nervous system diseases, including Parkinson's disease (PD), the second most common progressive neurodegenerative disorder of the central nervous system. PD affects the lives of several million people globally. It is caused by protein aggregation, such as in Lewy bodies, and the loss of dopamine-containing neurons in the substantia nigra of the midbrain. To our knowledge, six genes, including PARK2, SNCAIP, LRRK2, SNCA, SRRM2, and MAPT, are involved in aberrant AS events in PD patients. In this review, we highlight the relevance of aberrant AS in PD and discuss the use of an aberrant AS profile as a potential diagnostic or prognostic marker for PD and as a possible means of applying therapy.